Testing BMS-986511 in adults with major depressive disorder
Tests the drug BMS-986511 against placebo in adults with depression.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
Key facts
- Where
- Kladno, Klecany, Pilsen, and Prague, CzechiaSee the 6 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07772531, who can take part
Where in Czechia
- KladnoKladno, CzechiaNo longer taking part
- KlecanyKlecany, CzechiaNo longer taking part
- PilsenPilsen, CzechiaNo longer taking part
- PraguePrague, CzechiaNo longer taking part
- PraguePrague, CzechiaNo longer taking part
- PraguePrague, CzechiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07772531
- Record updated
- 4 September 2026
- Original description
A Study to Evaluate BMS-986511 in Adults with Major Depressive DisorderRead full original descriptionShow less
A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of BMS-986511 in Two Sequential Parts in Participants With Major Depressive Disorder
A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
Inclusion: Participants must meet the MDD diagnosis per DSM-5 criteria confirmed by structured interview; Participant must have current moderate to severe MDE confirmed by clinical assessment and validated scale; Participant must have current MDE duration >12 weeks at screening; Outpatient participants able to comply with study procedures; Participant require medication washout completed before baseline; Participant must have BMI within protocol range; Participants must meet reproductive safety requirements.
Exclusion: Participants must not have prior lifetime treatment with electroconvulsive therapy, ketamine/esketamine, deep brain stimulation, or transcranial magnetic stimulation; Participants must not have other primary psychiatric disorders or a history of treatment-resistant depression during the current episode; Participants must not have recent history of active suicidal ideation or attempt within the past year; Participants must not have recent history of alcohol/substance abuse or use of cannabis; Participants must not have significant ECG abnormalities, or poorly controlled diabetes; Other protocol defined inclusion/exclusion criteria apply.